Media

• Candel’s CEO looks to help ignite a new era of cancer treatments
• After flicker, investor enthusiasm for Candel burns brighter
• Newly public Candel looks to two years of value inflection points
• Candel Therapeutics, Inc NASDAQ Bell Ringing
• After building pipelines from GlaxoSmithKline to Flagship, Paul Peter Tak takes the helm at an under-the-radar oncolytic virus player
• Tak lands at Candel, with plans to speed up development of immunotherapy’s play late-stage assets
• Ex-GSK immunology chief takes over oncolytic virus biotech Candel as it ramps up its pipeline

2022

First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC
Charu Aggarwal, MD, MPH
ASCO 2022

Poster
5-minute video

2021

Phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma
Patrick Y. Wen, MD
26th Annual Meeting of the Society for Neuro-Oncology (SNO) 2021 Presentation

Detection of viral antigen and immune activation after intra-tumor injection of CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma
The Society for Immunotherapy of Cancer’s 36th Annual Meeting 2021 Poster

Patient experience with intraprostatic injection of CAN-2409 or placebo followed by valacyclovir in a phase 3 clinical trial for localized prostate cancer in combination with standard of care radiation therapy with or without androgen suppression
The 28th Annual Prostate Cancer Foundation’s Scientific Retreat 2021 Poster

Oncolytic Virus Immunotherapy, Tipping the balance in favor of the immune system to fight cancer
Paul Peter Tak, MD, PhD, FMedSci
Cambridge Healthtech Institute’s 9th Annual Immuno-Oncology Summit 2021 Presentation Video

Safety and Feasibility of Intraprostatic Injection of CAN-2409 or Placebo followed by Valacyclovir in Patients on Active Surveillance for Prostate Cancer (ULYSSES Trial)
Scott Eggener, MD
Fifth Global Summit on Precision Diagnosis and Treatment of Prostate Cancer 2021 Presentation

First in human clinical trial with CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma
E. Antonio Chiocca, MD PhD
ASCO Annual Meeting 2021 Presentation

Rahman et al. The Lancet Oncology (2021)
Leveraging external data in the design and analysis of clinical trials in neuro-oncology
Publication

Predina et al. Molecular Therapy (2020)
Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity
Publication

Kieran et al. Neuro-Oncology (2019)
Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma
Publication

Aggarwal et al. Molecular Therapy (2018)
Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion
Publication

Speranza et al. Neuro-Oncology (2018)
Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma
Publication

Wheeler et al. Neuro-Oncology (2016)
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma
Publication

Aguilar et al. Cancer Immunology, Immunotherapy (2015)
Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma
Publication